Drug Profile

CTX 187

Alternative Names: CTX-187

Latest Information Update: 31 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Altermune Technologies
Developer Centauri Therapeutics
Class Antibacterials; Peptide drug conjugates
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Gram-negative infections

Most Recent Events

16 Jun 2026 Phase-I clinical trials in Gram-negative infections in Netherlands (IV) (NCT07708116)
24 Feb 2026 Centauri Therapeutics plans a phase II trial for Gram-negative infections (unspecified route)
29 Jul 2025 Centauri Therapeutics plans first in human clinical study in Gram-negative infections in early 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com